Skip to main content

Drug Interactions between Mobic and naproxen

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

naproxen meloxicam

Applies to: naproxen and Mobic (meloxicam)

GENERALLY AVOID: Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy. Patients with a prior history of peptic ulcer disease and/or GI bleeding have a greater than 10-fold increased risk of developing a GI bleed during NSAID use compared to patients without a history. Additional risk factors include old age, alcohol use, smoking, and poor general health status.

MANAGEMENT: Concomitant use of more than one NSAID at a time should generally be avoided. Some authorities consider the concomitant use of more than one NSAID at a time to be contraindicated due to the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions (AU,UK). Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.

References

  1. "Product Information. Nalfon (fenoprofen)." Xspire Pharma PROD (2002):
  2. "Product Information. Indocin (indomethacin)." Merck & Co., Inc PROD (2002):
  3. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc PROD (2002):
  4. "Product Information. Anaprox (naproxen)." Roche Laboratories PROD (2006):
  5. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories PROD (2001):
  6. "Product Information. Daypro (oxaprozin)." Searle PROD (2001):
  7. "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim PROD (2001):
  8. "Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group (2006):
  9. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  10. Cerner Multum, Inc. "Australian Product Information." O 0
  11. "Product Information. Cambia (diclofenac)." Kowa Pharmaceuticals America (formerly ProEthic) (2009):
  12. "Product Information. Caldolor (ibuprofen)." Cumberland Pharmaceuticals Inc (2009):
  13. "Product Information. VIMOVO (esomeprazole-naproxen)." Astra-Zeneca Pharmaceuticals (2010):
  14. "Product Information. Duexis (famotidine-ibuprofen)." Horizon Therapeutics USA Inc (2011):
  15. "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc (2012):
  16. "Product Information. Etodolac ER (etodolac)." Taro Pharmaceuticals U.S.A. Inc (2016):
  17. "Product Information. Ketoprofen ER (ketoprofen)." Mylan Pharmaceuticals Inc (2016):
View all 17 references

Switch to consumer interaction data

Drug and food interactions

Moderate

naproxen food

Applies to: naproxen

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References

  1. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn PROD (2002):

Switch to consumer interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Nonsteroidal anti-inflammatories

Therapeutic duplication

The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category:

  • Mobic (meloxicam)
  • naproxen

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer